Cargando…
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 gene. Such alterations lead to a more aggressive behavior of the disease, but also predict response to treatments t...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Open Exploration
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400740/ https://www.ncbi.nlm.nih.gov/pubmed/36046143 http://dx.doi.org/10.37349/etat.2021.00037 |